

Index

Note: Page numbers of article titles are in **bold face** type.

A

- Abciximab, for endovascular procedures, 523–525, 528
 - for acute stroke, 465, 533–534
 - stent placement, 529–530
 - with thromboembolic complications, 532–533
- Aggregometry, optical, in antiplatelet activity measurement, 525
- Amplatz Goose Neck Snare, for embolectomy, 467
- Analgesia, cervical epidural microcatheterization technique for, 565–566
- Aneurysms, intracranial, **487–499**
 - clipping versus coiling for, **475–485**
 - coils for, **475–485**, 487–488
 - aneurysm factors in, 478–480
 - animal models of, 491–494
 - bioactive. *See* Bioactive coils.
 - clinical experience with, 494–497
 - dissecting, 483
 - efficacy of, 476–477
 - giant calcified, 483
 - large, 483
 - operator experience in, 480
 - patient factors in, 477–478
 - platelet interaction with, 518–519
 - ruptured, 482–483
 - safety of, 475–476
 - unruptured, 480–482
 - configuration of, treatment decisions and, 478–479
 - location of, treatment decisions and, 479–480
 - natural history of, after rupture, 482–483
 - partially treated, 543
 - pathogenesis of, 488–489
 - recanalization after, 489–491
 - repair mechanisms in, 488–489
 - risk factors for, 488
 - size of, treatment decisions and, 478
 - subarachnoid hemorrhage in. *See* Subarachnoid hemorrhage, aneurysmal.

- Angiojet rheolytic system, for embolectomy, 468
- Angioplasty, percutaneous balloon
 - for cerebral vasospasm, 501–507
 - for stroke, 468–469
- Anticonvulsants, for intracranial aneurysm, 541–542
- Antifibrinolytic therapy, for intracranial aneurysm, 543
- Antiplatelet therapy, for neuroendovascular techniques, **517–540**
 - activity measurement in, 525–526
 - acute stroke intervention, 533–534
 - clinical trials of, 526–529
 - for intracranial aneurysm, 542
 - pharmacology of, 520–525
 - platelet aggregation mechanisms and, 518–520
 - stent placement, 529–530
 - stroke prevention, 534–536
 - with intraoperative thromboembolism complications, 530–533
- Anti-Thrombotic Trialists Collaboration, 526
- Aspirin
 - for endovascular procedures, 520–521, 525–526, 528
 - stent placement, 530
 - with thromboembolic complications, 531, 533
 - for intracranial aneurysm, 542
 - for stroke prevention, 535
- Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH), 528

B

- Balloon angioplasty
 - for cerebral vasospasm, 501–507
 - for stroke, 468–469

- Balloon occlusion tolerance test, before neoplasm surgery, 547–549
- Basilar artery, aneurysms of, treatment decisions and, 479
- Benign tumors, endovascular surgery for, 547–549
- Bioactive coils, for intracranial aneurysm healing, **487–499**
 cytokine coated, 491–492
 extracellular matrix protein-coated, 491
 growth factor-coated, 491–492
 history of, 487
 hydrocoils, 493–494
 Matrix
 animal studies of, 492–493
 clinical studies of, 494–497
- Bleeding time, in antiplatelet activity measurement, 525
- Bone filter device, for kyphoplasty, 563
- Brachytherapy, carotid blow-out syndrome after, 550–553
- Brain
 access to, percutaneous intraspinal navigation in, 566
 aneurysms of. *See* Aneurysms, intracranial.
 vasospasm of. *See* Vasospasm, cerebral.
-
- C**
- Cancer
 carotid blow-out syndrome in, 550–553
 endovascular surgery for, 549–550
- CAPRIE (Clopidogrel Versus Aspirin in Individuals at Risk of Ischemic Events) study, 526–527, 535
- Carotid artery(ies)
 injury of, endovascular surgery for, 553–554
 perioperative compromise of, endovascular surgery for, 555–558
- Carotid blow-out syndrome, endovascular surgery for, 550–553
- Carotid cavernous fistula, traumatic, endovascular surgery for, 554–555
- Catheter(s). *See also* Neuroendovascular surgery.
 platelet interaction with, 518–519
- Cement, in vertebroplasty, 561–565
- Cerebral artery(ies)
 aneurysms of, treatment decisions and, 479
 balloon occlusion tolerance test of, before neoplasm surgery, 547–549
- Cerebrospinal fluid leak, after vertebroplasty, 564
- Cervical epidural microcatheterization, for analgesia, 565–566
- Chemical thrombolysis, ultrasonography with, 469
- Clipping, of aneurysms, **475–485**
 aneurysm factors in, 478–480
 dissecting, 483
 efficacy of, 476–477
 giant calcified, 483
 large, 483
 operator experience in, 480
 patient factors in, 477–478
 ruptured, 482–483
 safety of, 475–476
 unruptured, 480–482
- Clopidogrel
 for endovascular procedures, 521–523, 526–528
 stent placement, 529–530
 with thromboembolic complications, 531
 for intracranial aneurysm, 542
 for stroke prevention, 535–536
- Clopidogrel for the Reduction of Events during Observation study, 527
- Clopidogrel in Unstable Angina to Prevent Recurrent Events study, 527, 535
- Clopidogrel Versus Aspirin in Individuals at Risk of Ischemic Events study, 526–527, 535
- Coils, for aneurysms
 aneurysm factors in, 478–480
 bioactive. *See* Bioactive coils.
 dissecting, 483
 efficacy of, 476–477
 giant calcified, 483
 large, 483
 operator experience in, 480
 patient factors in, 477–478
 platelet interaction with, 518–519
 ruptured, 482–483
 safety of, 475–476
 unruptured, 480–482
- Collagen, in bioactive coils, for aneurysm healing, 491
- Communicating artery, anterior, aneurysms of, treatment decisions and, 479–480

Computed tomography, in stroke, protocol for, 471

Connective tissue growth factor, in aneurysm healing, 491

CREDO (Clopidogrel for the Reduction of Events during Observation) study, 527

CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) study, 527, 535

Cytokines
in bioactive coils, for aneurysm healing, 491–492
in intracranial aneurysm formation, 488

D

Dipyridamole
for endovascular procedures, 523
for stroke prevention, 535

E

EKOS MicroLysUS infusion catheter, for embolectomy, 469

Embolectomy
mechanical. *See* Mechanical embolectomy. surgical, 465

Embolization, endovascular
for carotid blow-out syndrome, 550–553
of neoplasms, 548–550
of vascular injury, 553–555

Endothelium, denudation of, in aneurysm formation, 489

Endovascular Photo Acoustic Recanalization laser system, 467–468

Endovascular surgery. *See* Neuroendovascular surgery.

EPIC study, antiplatelet agents in, 528

Epidural microcatheterization, cervical, for analgesia, 565–566

Epistaxis, endovascular surgery for, 558

EPISTENT study, antiplatelet agents in, 528

Eptifibatide, for endovascular procedures, 523–525

ESPRIT study, 535

Extracellular matrix proteins, in aneurysm healing, 491

F

Fibrinogen, in bioactive coils, for aneurysm healing, 491

Fibroblast(s), in bioactive coils, for aneurysm healing, 492

Fibroblast growth factor, in bioactive coils, for aneurysm healing, 492

Fibronectin, in bioactive coils, for aneurysm healing, 491

Fistula, carotid cavernous, endovascular surgery for, 554–555

Fixation, spinal, percutaneous, 566–567

G

Genetic factors, in intracranial aneurysms, 488

Glycoprotein IIb/IIIa inhibitors, for
endovascular procedures, 523–525, 528–529
stent placement, 529–530
with thromboembolic complications, 532–534

Goose Neck Snare, for embolectomy, 467

Growth factors, in bioactive coils, for aneurysm healing, 491–492

H

Healing, of intracranial aneurysms, bioactive coils for, **487–499**

Hemicraniectomy, for stroke, 544

Hemorrhage
in carotid blow-out syndrome, 550–553
reperfusion, in mechanical embolectomy, 472
subarachnoid, aneurysmal
intensive care for, 541–543
life expectancy estimation with, 478
management of, 482–483
mortality in, 475
prevention of, 480–482
recurrent, 482–483
traumatic, endovascular surgery for, 553–555

Heparin, for endovascular procedures, 531

Hereditary hemorrhagic telangiectasia, epistaxis in, 558

Hydrocoils, for aneurysm healing, 493–494

Hypertension, intracranial aneurysm risk in, 488–489

Hypophysectomy, trans-sphenoidal, vascular compromise in, 556

I

IMPACT II study, antiplatelet agents in, 528

Intensive care, in neuroendovascular surgery, **541–545**

Interferon- γ , in aneurysm healing, 491

International Subarachnoid Aneurysm Trial (ISAT), 541

ISAT (International Subarachnoid Aneurysm Trial), 541

K

Kyphoplasty, percutaneous, 561–565

L

Laminin, in bioactive coils, for aneurysm healing, 491

Laser thrombolysis, 467–468

LaTIS laser device, for embolectomy, 468

Leukocytes, in intracranial aneurysm formation, 488

M

Macrophages, in intracranial aneurysm formation, 488

Magnetic resonance imaging, in stroke, protocol for, 471

Malignant neoplasms, endovascular surgery for, 549–550

MATCH trial, antiplatelet agents in, 528

Matrix bioactive coils, for intracranial aneurysm healing
animal studies of, 492–493
clinical studies of, 494–497

Matrix metalloproteinases, in intracranial aneurysm formation, 488–489

Mechanical embolectomy, **463–474**
clinical trials of, 463–465
devices and techniques for, 465–469, 472
historical precedent of, 465
indications for, 469, 471–472
risks of, 472

Merci Retriever, for embolectomy, 465–467

Metastasis, spinal, percutaneous vertebroplasty for, 561–565

Monocytes, in intracranial aneurysm formation, 488

Myeloma, percutaneous vertebroplasty for, 561–565

N

Navigation, intraspinal, 566

Neoplastic disease, endovascular surgery for, 547–550

Nerve root compression, after vertebroplasty, 564

Neuroendovascular surgery
antiplatelet therapy in, **517–540**, 542
bioactive coils in, **487–499**
clipping versus coiling decisions in, **475–485**
for cerebrovasospasm, **501–516**
for head and neck vascular lesions, **547–560**
intensive care in, **541–545**
mechanical embolectomy, **463–474**

Neuronet Endovascular Snare, for embolectomy, 467

Nicardipine, endovascular, for cerebral vasospasm, 513

Nimodipine, for cerebral vasospasm, 543

Nosebleed, endovascular surgery for, 558

O

Optical aggregometry, in antiplatelet activity measurement, 525

Osteoplasty, spinal, percutaneous, 561–565

Osteoporosis, vertebroplasty for, 561–565

P

Pain, neck and back, percutaneous spinal fixation for, 566–567

Papaverine, endovascular, for cerebral vasospasm, 507–513

Pedicle screws, percutaneous insertion of, 566–567

Percutaneous balloon angioplasty
for cerebral vasospasm, 501–507
for stroke, 468–469

Phenytoin, for intracranial aneurysm, 541–542

Pituitary tumor, excision of, vascular compromise in, 556

Platelet(s), aggregation of
mechanisms of, 518–520
prevention of. *See* Antiplatelet therapy.

Platelet-derived growth factor, in bioactive coils,
for aneurysm healing, 492

Polyglycolic acid, in bioactive coils, for aneurysm
healing, 493

Polyglycolic/poly-L-lactic acid copolymer, in
bioactive coils, for aneurysm healing, 493

Polymethylmethacrylate vertebroplasty, 561–565

Prevention Regimen for Effectively Avoiding
Secondary Strokes study, 535

PRoFESS (Prevention Regimen for Effectively
Avoiding Secondary Strokes) study, 535

Pseudoaneurysm, traumatic, endovascular
surgery for, 553

R

Randomized Efficacy Study of Tirofiban for
Outcomes and Restenosis (RESTORE), 528

Rapid platelet function assay, 526

RESTORE (Randomized Efficacy Study of
Tirofiban for Outcomes and Restenosis), 528

Rods, inflatable, in percutaneous spinal
fixation, 567

S

Screw fixation, of spine, percutaneous, 566–567

Smoking, intracranial aneurysm risk in, 488–489

Spinal cord, compression of, after vertebroplasty,
564

Spine, percutaneous interventions for, **561–568**
epidural microcatheterization, 565–566
fixation, 566–567
intraspinous navigation, 566
osteoplasty, 561–565

Stents
antiplatelet therapy with, 529–530
for carotid artery injury, 554
for carotid blow-out syndrome, 552–553
for ischemic stroke, 468–469
platelet interaction with, 518–519

Stroke, ischemic
intensive care for, 543–544
mechanical embolectomy for, 463–474

percutaneous interventions for, antiplatelet
therapy with, 533–534
prevention of, antiplatelet therapy for, 534–536

Subarachnoid hemorrhage, aneurysmal
intensive care for, 541–543
life expectancy estimation with, 478
management of, 482–483
mortality in, 475
prevention of, 480–482
recurrent, 482–483

Subarachnoid space, spinal, cerebral access
through, 566

T

Thromboembolism, in endovascular procedures,
antiplatelet therapy for, 530–533

Thrombolysis in Myocardial Infarction study, 533

Thrombospondin-1, in aneurysm healing, 491

Thrombus, mechanical removal of. *See*
Mechanical embolectomy.

Ticlopidine
for endovascular procedures, 521–523
for stroke prevention, 535

TIMI (Thrombolysis in Myocardial Infarction)
study, 533

Tirofiban, for endovascular procedures, 523–525,
528, 534

Tissue necrosis factor- α , in aneurysm healing, 491

Tissue plasminogen activator
for endovascular procedures, with
thromboembolic complications, 532, 534
for stroke, 469, 543–544
versus mechanical embolectomy, 463, 465
intraventricular, for intracranial aneurysm,
542

Transforming growth factor- β , in aneurysm
healing, 491–492

Trauma, vascular, endovascular surgery for,
553–555

Tumors, endovascular surgery for, 547–550

U

Ultrasonography, in embolectomy, 469

Urokinase, for endovascular procedures, with
thromboembolic complications, 532

V

Vascular compromise, perioperative,
 endovascular surgery for, 555–558

Vascular endothelial growth factor, in bioactive
 coils, for aneurysm healing, 492

Vasospasm, cerebral
 endovascular treatment of, **501–516**, 543
 nicardipine in, 513
 papaverine in, 507–513
 transluminal balloon angioplasty in,
 501–507
 in intracranial aneurysm, 543

Ventricles
 drainage of, for intracranial aneurysm, 542
 tissue plasminogen activator administration to,
 for intracranial aneurysm, 542

Vertebral-jugular fistula, endovascular surgery for,
 553

Verify Now system, for antiplatelet activity,
 526

Vertebral artery(ies)
 balloon occlusion tolerance test of, before
 neoplasm surgery, 547–549
 injury of, endovascular surgery for, 553

Vertebroplasty, percutaneous, 561–565

Vitronectin, in bioactive coils, for aneurysm
 healing, 491

X

X-sizer Catheter system, for embolectomy, 468